



# HHS Public Access

Author manuscript

*Br J Haematol.* Author manuscript; available in PMC 2016 March 08.

Published in final edited form as:

*Br J Haematol.* 2015 November ; 171(4): 638–646. doi:10.1111/bjh.13641.

## Coagulation activation in sickle cell trait: an exploratory study

Chirag Amin<sup>1</sup>, Soheir Adam<sup>1</sup>, Micah J. Mooberry<sup>1</sup>, Abdullah Kutlar<sup>2</sup>, Ferdane Kutlar<sup>2</sup>, Denise Esserman<sup>3</sup>, Julia E. Brittain<sup>4</sup>, Kenneth I. Ataga<sup>1</sup>, Jen-Yea Chang<sup>1</sup>, Alisa S. Wolberg<sup>5</sup>, and Nigel S. Key<sup>1,5</sup>

<sup>1</sup>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

<sup>2</sup>Department of Medicine, Georgia Regents University, Augusta, GA

<sup>3</sup>Department of Biostatistics, School of Public Health, Yale University, New Haven, CT

<sup>4</sup>Department of Cell Biology and Anatomy, Georgia Regents University, Augusta, GA

<sup>5</sup>Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA

### Summary

Recent epidemiologic data suggest that sickle cell trait (HbAS; AS) is a risk factor for venous thromboembolism. We conducted an exploratory study of healthy subjects with AS under baseline conditions to determine whether a chronic basal hyperactivation of coagulation exists, and if so, what mechanism(s) contribute to this state. Eighteen healthy AS individuals were compared to 22 African-American controls with a normal haemoglobin profile (HbAA; AA) and 17 patients with sickle cell disease (HbSS; SS). Plasma thrombin-antithrombin complexes and D-dimer levels were elevated in AS relative to AA patients ( $P = 0.0385$  and  $P = 0.017$ , respectively), and as expected, were much higher in SS *versus* AA ( $P < 0.0001$  for both). Thrombin generation in platelet poor plasma was indistinguishable between AA and AS subjects, whereas a paradoxical decrease in endogenous thrombin potential was observed in SS ( $P = 0.0001$ ). Whole blood tissue factor was elevated in SS compared to AA ( $P = 0.005$ ), but did not differ between AA and AS. Plasma microparticle tissue factor activity was non-significantly elevated in AS ( $P = 0.051$ ), but was clearly elevated in SS patients ( $P = 0.004$ ) when compared to AA controls. Further studies in larger cohorts of subjects with sickle cell trait are needed to confirm the results of this preliminary investigation.

### Keywords

sickle; venous thrombosis; tissue factor; coagulation; thrombin

---

Correspondence: Dr Nigel S. Key, Department of Medicine, Division of Haematology/Oncology, 1079 Genetic Medicine Building, CB #7035, Chapel Hill, NC 27599, USA. nigel\_key@med.unc.edu.

#### Authorship and disclosures

NSK was the principal investigator and takes primary responsibility for the paper. CA, SA and KIA recruited the study subjects; CA, MJM, AK, FK, JEB, J-YC, and ASW performed the laboratory assays; DE was primarily responsible for statistical analysis; NSK coordinated the research; NSK and ASW wrote the paper. The authors report no potential conflicts of interest.

#### Supporting Information

Additional Supporting Information may be found in the online version of this article:  
Table S1. Plasma inflammatory marker and cytokine levels.

As many as 200 million people worldwide are heterozygous carriers of a mutation in the *HBB* gene (*HBB* E6V, also termed HbS mutation or 'sickle gene'), resulting in a condition known as sickle cell trait (HbAS, hereafter termed AS) (Piel *et al*, 2013) (Dr. S. Grosse, personal communication, US Centers for Disease Control and Prevention, Atlanta, GA). Although traditionally viewed as a benign carrier state, AS may be a risk factor for certain adverse outcomes, including venous thromboembolism (VTE) (Tsaras *et al*, 2009; Key & Derebail, 2010; Key *et al*, 2015). In a large case-control study of VTE in African-American subjects, we reported that AS was associated with an increased risk of VTE, with an odds ratio (OR) of about 2; more strikingly, AS appeared to confer a particularly high risk for pulmonary embolism (PE) (OR  $\approx$  4) (Austin *et al*, 2007). In addition, a possible interaction between AS and hormonal contraceptive usage may further heighten the risk of VTE in women of reproductive age (Austin *et al*, 2009). Other studies have also reported an association between AS and risk of VTE, particularly PE (Heller *et al*, 1979; Bucknor *et al*, 2014; Folsom *et al*, 2015). This association was deemed a high priority area for further research in a recent National Institutes of Health conference on sickle cell trait (Goldsmith *et al*, 2012).

It has previously been reported that plasma levels of the 'pre-thrombotic' biomarkers thrombin-antithrombin complexes (TAT), prothrombin fragments 1 + 2 and D-dimers are elevated in subjects with AS compared to race-matched controls (Westerman *et al*, 2002). One additional study demonstrated elevated TAT complex levels in AS compared to non race-matched controls (Helley *et al*, 1997). However, comparison with race-matched controls is essential as both pre-thrombotic markers, such as D-dimer (Lutsey *et al*, 2006), and plasma thrombin generation (Roberts *et al*, 2013) are higher in healthy individuals of African descent.

In the present report, we sought to confirm the presence of a pre-thrombotic state in healthy subjects with AS using plasma markers of coagulation activation. Simultaneously, we investigated possible mechanisms that might account for the hypercoagulable state in AS subjects compared to healthy HbAA (AA) controls, as well as subjects with sickle cell disease (SCD; HbSS; SS), in whom a complex and multi-causal state of activation of coagulation has been well described (Ataga & Key, 2007; Lim *et al*, 2013). The choice of analytes was influenced by these prior studies, which have focused on both the trigger for coagulation activation in SS, such as circulating tissue factor (TF, also termed coagulation Factor III) (Key *et al*, 1998; Colella *et al*, 2012; Setty *et al*, 2012), as well as 'downstream' enhancement of thrombin generation capacity (Hemker *et al*, 2006; Gerotziafas *et al*, 2012; Lim *et al*, 2013; Noubouossie *et al*, 2013).

## Methods

### Study subjects

This exploratory cohort study was conducted at the University of North Carolina at Chapel Hill. Institutional Review Board approval was obtained and written informed consent was obtained from all study participants. The study included only African-Americans between the ages of 18 and 65 years. Ethnicity/race was self-declared.

Subjects were recruited into three study categories: Group 1 or controls (AA) included subjects without any haemoglobinopathy; Group 2 included subjects with sickle cell trait (AS); and Group 3 included subjects with SCD (SS) with either HbSS or HbS- $\beta$ thal<sup>0</sup> genotype. Exclusion criteria included the presence of a prior history of VTE, current pregnancy or use of hormonal contraceptive therapy and current use of anticoagulants or anti-platelet agents (the latter within the past 7 days). Subjects with SCD were also excluded if they had experienced a recent (<4 weeks) pain crisis or and/or hospitalization, had recently (<3 months) undergone surgery, or if they had received blood transfusion within the last 3 months. No subject in any group had diabetes mellitus or hypertension, cancer or an acute or chronic inflammatory disorder.

### Phlebotomy and plasma preparation

After discarding the first 3 ml of blood, blood was drawn into appropriate commercial vacutainer or pre-prepared tubes and rapidly mixed. Samples obtained from a less than fully satisfactory venipuncture were discarded. For D-dimer and TAT analysis, blood was drawn into 3.2% sodium citrate. For thrombin generation and clot formation analyses, blood was drawn into 3.2% sodium citrate/18.5  $\mu$ g/ml corn trypsin inhibitor to prevent contact activation (Luddington & Baglin, 2004). In each case, platelet-free plasma was prepared by centrifugation, followed by a second centrifugation step at 13 000 *g* for 2 min. Plasma aliquots were stored at  $-80^{\circ}\text{C}$  until batched analysis could be performed. Frozen plasma samples were thawed rapidly at  $37^{\circ}\text{C}$  immediately prior to assay and discarded after use.

### Materials

Factor VIIa and factor X were from Enzyme Research Laboratories, Inc. (South Bend, IN, USA). Chromogenic substrate Pefachrome FXa 8595 was from Centerchem, Inc. (Norwalk, CT, USA). Re-lipidated recombinant human TF (Innovin<sup>®</sup>) was from Siemens Healthcare Diagnostics Products GmbH (Marburg, Germany). Immunbind TF enzyme-linked immunosorbent assay (ELISA) kits were from American Diagnostica, Inc (Stamford, CT, USA). An inhibitory monoclonal antibody (HTF1) to TF was a kind gift from Ronald Bach, PhD (Minneapolis VA Medical Center, Minneapolis, MN, USA). Corn trypsin inhibitor was from Hematologic Technologies, Inc. (Essex Junction, VT, USA). Unilamiellar phospholipid vesicles [15% phosphatidylserine (PS), 41% phosphatidylcholine (PC) 41% and phosphatidylethanolamine (PE) 44%] were prepared as described (Hope *et al*, 1985).

### Haematology profile

Routine haematological assays were performed using standard methods at the McClendon Clinical Laboratories at the University of North Carolina Memorial Hospital. Because the laboratory reports markedly low or undetectable serum haptoglobin values as '<220 mg/l', this parameter was treated as a categorical variable, and observed values were divided into those that were below (<220 mg/l), within (220–1390 mg/l) and above (>1390 mg/l) the laboratory's quoted normal reference range.

### Plasma D-dimer and thrombin-antithrombin (TAT) complexes

D-dimer on plasma samples was measured in the clinical laboratory using the HemosIL® D-Dimer HS immuno-turbidic assay on an ACL TOP® coagulation analyser (Instrumentation Laboratory, Bedford, MA, USA) (Salvagno *et al*, 2008). Because the laboratory reports markedly low D-dimer values as '<150 µg/ml', plasma D-dimer values were treated as a categorical variable, dividing observed values into those that were below (<150 µg/ml), within (150–229 µg/ml) and above (>229 µg/ml) the laboratory's quoted normal reference range. Plasma TAT levels were determined by using an ELISA assay kit from Affinity Biologicals (Lancaster, ON, Canada).

### Thrombin generation and fibrin formation in plasma

Thrombin generation was measured fluorometrically using Calibrated Automated Thrombography (CAT), as previously described (Machlus *et al*, 2009), using the TF and phospholipid reagents (final concentration, 1 pmol/l and 4 µmol/l, respectively) supplied by the manufacturer (Thromboscope BV, Maastricht, Netherlands). Parameters of interest included: (i) lag time; (ii) time to peak thrombin generation; (iii) peak thrombin level; and (iv) area under the curve ['endogenous thrombin potential' (ETP)].

Fibrin formation was measured turbidimetrically by continuous measurement of absorbance at 405 nm in a Spectramax microplate reader (Molecular Devices, Sunnyvale, CA, USA). Here, platelet-free plasma samples were re-calcified, and clotting was initiated by addition of Innovin® (1:60 000 dilution, final) and phospholipid vesicles (125 µmol/l, final), as previously described (Gray *et al*, 2011). Endpoints of interest included: (i) onset of fibrin formation; (ii) rate of fibrin formation; and (iii) absolute change in turbidity from baseline.

### Microparticle tissue factor activity

As previously described (Key & Mackman, 2010), microparticles (MPs) were isolated from citrate anticoagulated platelet-free plasma by centrifugation at 20 000 *g* for 30 min. The pellet was re-suspended in HBSA (20 mmol/l HEPES, pH 7.4, 150 mmol/l NaCl, and 1 mg/ml bovine serum albumin) and re-centrifuged at 20 000 *g* for 30 min, before final re-suspension in 250 µl HBSA. MPs were incubated with factor VIIa (100 pmol/l, final) and factor X (135 nmol/l, final), in the presence of calcium (5 mmol/l, final) and anti-TF antibody (HTF1, 10 µg/ml final) or IgG control. Factor Xa generation was measured in aliquots by chromogenic substrate cleavage as described. Specific TF activity (fmol/l) was determined by subtracting the rate of factor Xa generated in the presence of HTF1 from the rate of factor Xa generated in the presence of IgG controls with reference to a standard curve generated using lipidated recombinant human TF (In-novin®). Effective TF concentration in each lot of Innovin® was calculated as previously described (Johnson *et al*, 2009).

### Whole blood tissue factor activity

As previously described (Key *et al*, 1998), frozen whole blood samples were thawed at 37°C for 3 min, after which 250 µl was added to 900 µl TBS-EDTA (20 mmol/l Tris-HCl, pH 7.5, 150 mmol/l NaCl, 100 mmol/l EDTA) and mixed by vortexing. Following three freeze-thaw cycles, sample pellets were prepared by high-speed centrifugation (100 000 *g* at 4°C for 60

min) and washed three times in TBS-EDTA before final suspension of the pellet in 250 µl HBSA. One hundred microlitre was incubated with HTF1 (4 µg/ml) or control antibody for 60 min. Forty microlitre of each sample was then added to a 96-well plate in duplicate. Forty microlitre of factor mix (2 nmol/l factor VIIa and 300 nmol/l factor X in HBSA with 5 mmol/l calcium) was then added to each well. Plates were incubated at 37°C for 2 h before adding 10 µl of EDTA. Forty microlitre of the chromogenic substrate, Pefachrome FXa 8595 (final concentration 0.3 mmol/l) was added to each well. The rate of factor Xa cleavage of the chromogenic substrate at room temperature in each well was monitored in a *ThermoMax*<sup>®</sup> plate reader (Molecular Devices, Sunnyvale, CA, USA). Innovin<sup>®</sup> at various concentrations was used as the TF standard. TF-dependent procoagulant activity (pmol/l) was defined as the difference between the rates of factor Xa cleavage of substrate in the absence/presence of HTF1.

### Inflammatory markers and cytokines

Cytokine and chemokine levels in citrated plasma were determined by colourimetric bead assay using the Luminex system and human-specific bead sets (R&D Systems, Minneapolis, MN, USA). Results were interpolated from 5-parameter-fit standard curves generated using the relevant recombinant human proteins (R&D Systems).

### Statistical analysis

The primary goal of the study was to explore differences in coagulation and inflammatory parameters between subjects with AS and matched controls (AA). Patients with SS were included as a positive control and to examine whether any gene dosing effects were evident. The study had planned to enrol 20 subjects from each subtype (AA, AS and SS). As this was an exploratory study, sample size was estimated from prior studies that used similar assays in individuals with SS disease (Westerman *et al*, 2002; Ataga *et al*, 2008).

Descriptive analyses were performed to explore the distribution of each variable or analyte. Data for continuous variables were expressed as median values with interquartile ranges (IQR), and compared between groups (AA vs. AS and AA vs. SS) using the Mann–Whitney *U* test. For categorical data (D-dimers and haptoglobin), groups were compared using Fisher's exact test. Spearman rank correlation was used to determine correlation between variables; in the case of a categorical variable (such as D-dimers), a rank of 1 was given to values falling below the reference range, a rank of 2 to values within the range, and a rank of 3 to values above the quoted reference range. Significance was established at the 0.05 level; no adjustments were made for multiple comparisons, because this was an exploratory study.

## Results

### Study subject characteristics

Fifty-seven African-American subjects were recruited: 22 AA, 18 AS and 17 SS. Age was comparable amongst the groups with median ages of 37.5 (IQR: 32–45), 38.5 (IQR: 33–45) and 41 (IQR: 24.5–47.5) years for AA, AS, and SS, respectively. Ninety-one per cent of the AA controls were females, while females accounted for 56% of the AS subjects and 53% of the SS subjects.

As expected, haemoglobin levels were similar for AA and AS subjects, but were substantially lower among those with SS, in whom anaemia was accompanied by evidence of accelerated haemolysis – specifically, higher serum lactate dehydrogenase (LDH) and lower haptoglobin values (Table I). Reticulocyte counts were not obtained. There was a trend towards lower serum haptoglobin and, to a lesser extent, higher serum LDH values in AS compared to control subjects. Total white blood cell counts were also higher in the SS group; this was accounted for by an increase in both absolute neutrophil and absolute monocyte counts. There was a trend towards elevated absolute monocyte counts in AS subjects. Platelet counts were higher in the SS group, but it is noteworthy that they were also marginally higher ( $P = 0.0474$ ) in AS subjects (median:  $325 \times 10^9/l$ ; IQR:  $290\text{--}364 \times 10^9/l$ ) compared to AA controls (median:  $285 \times 10^9/l$ , IQR:  $255\text{--}327 \times 10^9/l$ ).

### Coagulation is activated in vivo in both SS and AS

D-dimer levels were elevated in every patient with SS, with a highly significant increase compared to controls ( $P < 0.0001$ ) (Table II). However, D-dimer levels were also elevated in AS relative to AA ( $P = 0.017$ ). It should be noted that D-dimers were above the laboratory's reference range in 5 of 22 (23%) subjects in the AA control group. This probably reflects the fact that D-dimer levels are elevated in African-Americans compared to white Americans (Lutsey *et al*, 2006), who comprise the large majority of healthy subjects from whom the reference ranges are derived in the clinical laboratory.

Plasma TAT complexes showed similar results, with a marked increase in SS ( $P < 0.0001$ ) and a more modest but significant increase in AS ( $P = 0.0385$ ) (Table II). Notably, in the case of both the AS and SS groups, the distribution of values included a substantial number of subjects whose TAT levels overlapped with AA controls, and the overall differences between the groups and controls was driven by the population of outliers (data not shown). For the entire group of study subjects, TAT complexes and D-dimers were moderately well correlated, with a Spearman correlation coefficient of 0.55 ( $P < 0.0001$ ).

### Thrombin generation capacity and fibrin formation in AS or SS plasma are not increased

We next examined whether the capacity for thrombin generation is increased in the plasma of AS and SS subjects *ex vivo*, as elevated plasma TAT complexes point to the presence of accelerated thrombin generation *in vivo*. By CAT assay, neither lag time nor peak thrombin generation differed between the three groups (Table III). However, time to peak thrombin generation was shorter in SS vs. AA ( $P = 0.0001$ ) (Fig 1). Unexpectedly, ETP was lower in patients with SS vs. AA ( $P = 0.0001$ ). Subjects with AA and AS did not differ in any CAT parameter.

Fibrin formation in plasma was also measured using a turbidimetric assay. The onset of fibrin formation was more rapid in SS compared to AA ( $P = 0.0418$ ), although the subsequent rate of fibrin formation did not differ (Fig 2, Table III). The more rapid onset of fibrin formation in SS is consistent with the shorter time to peak thrombin generation in the CAT assay (Fig 1). Neither the rate, nor the change in turbidity (an indicator of fibrin network structure) differed significantly between AA and SS individuals. No changes were

noted in any of the measured parameters when AA and AS subjects were compared, also consistent with the thrombin generation assay data.

### **Microparticle TF procoagulant activity in AS**

As described in Methods, circulating TF activity was measured using two separate assays – one for TF procoagulant activity in whole blood (WB-TF), and one for MP-associated TF (MP-TF) activity in cell free plasma. As previously reported (Key *et al*, 1998), WB-TF activity was elevated in SS disease compared to AA controls ( $P = 0.005$ ). However, WB-TF did not differ between AA and AS subjects ( $P = 0.734$ ) (Fig 3A). MP-TF procoagulant activity showed a trend towards being elevated in AS subjects ( $P = 0.051$ ), and was clearly increased in SS subjects ( $P = 0.004$ ) compared to controls (Fig 3B).

MP-TF activity levels and TAT complexes were only weakly correlated for the entire group (AA, AS and SS), with a coefficient of 0.30 ( $P = 0.0295$ ). In addition, the correlation between MP-TF and D-dimers was only 0.28 ( $P = 0.0381$ ), but this may have been influenced by the fact that D-dimer was treated as a categorical variable with only three levels. WB-TF did not correlate with TAT or D-dimer as evidenced by coefficients of 0.01 ( $P = 0.9215$ ) and 0.16 ( $P = 0.2442$ ), respectively.

### **Inflammatory markers and cytokine levels are not elevated in AS**

Several markers, including soluble CD40 ligand ( $P = 0.0276$ ), tumour necrosis factor (TNF  $\alpha$ ;  $P = 0.0003$ ) and soluble vascular cell adhesion molecule 1 (VCAM1;  $P < 0.0001$ ) were elevated in SS compared to AA controls, whereas epithelial-derived neutrophil-activating peptide 78 [ENA78 (CXCL5);  $P = 0.0276$ ] and granulocyte colony-stimulating factor ( $P = 0.0304$ ) were significantly reduced (Table S1). C-reactive protein, an acute phase response marker that has been reported to be elevated in SS patients (Singhal *et al*, 1993), was not increased in this cohort. The inflammatory markers C-reactive protein, TNF  $\alpha$ , interleukin (IL) 1- $\alpha$ , IL1 $\beta$ , IL6, and IL8 also did not differ between AA and AS subjects. Soluble P-selectin levels trended higher in both AS ( $P = 0.0551$ ) and SS ( $P = 0.0577$ ) subjects, but without an apparent 'gene dosing effect' observed in these groups.

## **Discussion**

Elevated levels of plasma D-dimers, and to a lesser extent, TAT complexes in this study are consistent with a previous report that coagulation is more activated in healthy subjects with AS compared to race-matched controls (Westerman *et al*, 2002). However, further larger scale studies will be required to definitely establish this association. We also included a cohort of patients with SS, and observed the expected pronounced elevation in the pre-thrombotic markers in plasma (TAT complexes and D-dimers) compared to controls. Whether or not activation of coagulation in SS patients contributes to vaso-occlusive complications, such as pain crisis, stroke, or pulmonary hypertension remains an open question (Hillery & Panepinto, 2004; Ataga & Key, 2007; Pakbaz & Wun, 2014), but several pieces of evidence now support the conclusion that the risk of VTE is increased not only in SCD (Stein *et al*, 2006; Novelli *et al*, 2012; Naik *et al*, 2014), but also in sickle trait (Austin *et al*, 2007; Bucknor *et al*, 2014; Folsom *et al*, 2015). We examined whether

thrombin-generating capacity in AS and SS plasma is increased in parallel with the increased levels of circulating TAT and D-dimers. Paradoxically, ETP was reduced in individuals with SS (Fig 1). Several groups have addressed the question whether thrombin generation in plasma is elevated in SCD, with mixed and sometimes opposite conclusions (Lim *et al*, 2013). Notably, an analogous discrepancy between elevated TAT and/or D-dimer *in vivo* and normal or decreased ETP *ex vivo* has been described elsewhere, for example in normal pregnancy (Eichinger *et al*, 1999). When performed in cell-free plasma, ETP is dependent on the net balance between levels of procoagulant and anticoagulant factors (Machlus *et al*, 2009), and therefore the combination of elevated procoagulants, such as FVIII and reduced anticoagulants (such as protein C and protein S) in SCD might be expected to result in a net increase in thrombin generation potential. Beta thalassaemia syndromes, particularly after splenectomy, represent another haemoglobinopathy that is associated with *in vivo* evidence of coagulation hyperactivation and a clinical risk of thrombotic events (Ataga *et al*, 2007). Tripodi *et al* (2009) demonstrated that while whole blood thrombelastometry end points were suggestive of a hypercoagulable state in  $\beta$ -thalassaemia, plasma thrombin generation profiles were normal. The authors concluded that abnormalities in blood cell number or function – as opposed to plasma proteins – contribute to the hypercoagulability in  $\beta$ -thalassaemia. The apparent discrepancy between increased plasma TAT levels and reduced ETP in this study may be indicative of a similar situation in SCD.

Some of the well-recognized complications of SCT include hyposthenuria, renal papillary necrosis, renal medullary carcinoma, splenic infarction at high altitude, glaucoma following hyphema of the anterior chamber of the eye, exertional rhabdomyolysis and exercise-related sudden death (Tsaras *et al*, 2009; Hooper *et al*, 2010; Key & Derebail, 2010). Common to all these scenarios is the likelihood that sickling of erythrocytes occurs in a vascular bed that may be either continuously or intermittently exposed to conditions that favour sickle haemoglobin polymerization, including hypoxia (e.g. in the anterior chamber of the eye or in the splenic microvasculature at high altitude), acidosis or hyperosmolarity (e.g. in the renal medulla).

We evaluated whether some of the mechanisms believed to contribute to activation of coagulation in SS (Ataga & Key, 2007) might also be at play in AS. By analogy to SCD, we evaluated whether circulating TF levels are elevated in individuals with SCT. We, and others have previously reported that cell-associated TF levels are elevated in patients with SCD (Key *et al*, 1998; Colella *et al*, 2012; Setty *et al*, 2012). The present study confirmed that finding, but failed to demonstrate any increase in WB-TF in AS subjects (Fig 3A). The finding of increased MP-TF activity in SS subjects (Fig 3B) is consistent with our previous observation (Key *et al*, 1998), but may be at odds with the study by van Beers *et al* (2009). These authors also found that erythrocyte and platelet MP numbers were elevated in SCD, but reported that thrombin generation was dependent on factor XI, but not factor VII, thereby implicating the ‘intrinsic’ coagulation pathway. This discrepant observation probably reflects technical differences, most notably the presence of plasma in the assay reported by van Beers *et al* (2009). In this study, we were surprised to find marginal, albeit insignificantly elevated levels of MP-TF procoagulant activity in subjects with AS (Fig 3B).



However, the absent or modest correlations between WB-TF and MP-TF activities (respectively) question whether circulating TF is the dominant mechanism contributing to activation of coagulation *in vivo*. Indeed, the role of circulating MP-TF as a mediator of coagulation activation and thrombosis in human disease states has been extensively studied, although with mixed conclusions to date (Owens & Mackman, 2011; Geddings & Mackman, 2013; Lacroix *et al*, 2013).

In addition, we evaluated whether a number of pro-inflammatory cytokines are elevated in subjects with AS, as is the case in SS (Hoppe, 2014). It is well established that one mechanism contributing to the 'cross talk' between inflammation and coagulation is mediated by certain pro-inflammatory cytokines, such as TNF- $\alpha$ , and IL1 and 6 (Levi & van der Poll, 2010; Engelmann & Massberg, 2013; Sparkenbaugh & Pawlinski, 2013). However, in this study, we were unable to demonstrate any significant increase in these inflammatory markers in AS subjects. Consistent with our results, Tripette *et al* (2010) found no difference in baseline levels of multiple cytokines and soluble adhesion molecules [TNF $\alpha$ , IL6, soluble (s) Intercellular Adhesion Molecule 1 (ICAM1), sVCAM1, sP-selectin and sL-selectin] in patients with SCT, although differences were observed following a sub-maximal exercise protocol.

Several limitations of this study warrant discussion. We did not perform formal age- and sex-matching among the three cohorts, which resulted in a greater preponderance of females among the control group. Secondly, because this was designed as an exploratory study, the relatively small sample size may have limited our ability to draw definitive conclusions about the role of any single mechanism in the hyper-activation of coagulation in AS. Indeed, by analogy to the complexity of the hypercoagulability in SS, other candidate mechanisms may also contribute to the excessive activation of coagulation in subjects with AS. For example, we have recently evaluated erythrocyte PS expression in subjects with AS. While we have not observed any increase in AS subjects compared to controls at baseline in preliminary studies, we have detected a significant increase in red cell PS expression in AS subjects on haemodialysis compared to matched controls. Furthermore, red cell PS expression was highly correlated with plasma TAT levels (Brittain *et al*, 2010). These data suggest that a 'second hit', which might include extreme hypoxia in the renal medulla or the venous valvular pockets in the lower extremity (Sevitt, 1974; Hamer *et al*, 1981), may be required to perturb AS red cells, and thereby promote their ability to contribute to activation of coagulation. We are continuing to evaluate this and other possibilities with the ultimate goal of identifying biomarkers of thrombotic risk that may be present in sickle haemoglobinopathies.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors would like to thank Dr. David Barrow, Dell Strayhorn RN FNP, Susan Jones RN, Ben Hulkower, Patrick Moody and Laura Gray for their excellent technical assistance. The authors also acknowledge funding from the North Carolina TRACS Institute (UL1TR000083), UO1HL117659 (NSK and KIA), T32HL007149 (CA, SA


and MJM), K12HL087097 (MJM), R01 HL094740 (ASW) and the Doris Duke Charitable Foundation (NSK), and Yale CTSA (UL1TR000142).

## References


- Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. *Hematology Am Soc Hematol Educ Program*. 2007;91–96. [PubMed: 18024615]
- Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. *British Journal of Haematology*. 2007; 139:3–13. [PubMed: 17854302]
- Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohler C, Hinderliter A, Parise LV, Orringer EP. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. *Haematologica*. 2008; 93:20–26. [PubMed: 18166781]
- Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC. Sickle cell trait and the risk of venous thromboembolism among blacks. *Blood*. 2007; 110:908–912. [PubMed: 17409269]
- Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. *American Journal of Obstetrics and Gynecology*. 2009; 200:e621–e623.
- van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, Meijers JC, Biemond BJ, CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. *Haematologica*. 2009; 94:1513–1519. [PubMed: 19815831]
- Brittain JE, Derebail VK, Mooberry MJ, Ataga KI, Kshirsagar AV, Key NS. Increased red cell phosphatidylserine exposure correlates with enhanced thrombin generation in sickle trait patients with end stage renal disease. *Blood*. 2010; 116 Abstract 2665.
- Bucknor MD, Goo JS, Coppolino ML. The risk of potential thromboembolic, renal and cardiac complications of sickle cell trait. *Hemoglobin*. 2014; 38:28–32. [PubMed: 24099594]
- Colella MP, De Paula EV, Conran N, Machado-Neto JA, Annicchino-Bizzacchi JM, Costa FF, Saad ST, Traina F. Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. *Journal of Thrombosis and Haemostasis*. 2012; 10:1967–1970. [PubMed: 22817333]
- Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, Kittl EM, Brenner B, Mannhalter C, Lechner K, Kyrle PA. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. *Thrombosis and Haemostasis*. 1999; 82:1232–1236. [PubMed: 10544904]
- Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nature Reviews Immunology*. 2013; 13:34–45.
- Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, Lutsey PL, Naik R, Pankow JS, Grove ML, Basu S, Key NS, Cushman M. Prospective study of sickle cell trait and venous thromboembolism incidence. *Journal of Thrombosis and Haemostasis*. 2015; 13:2–9. [PubMed: 25393788]
- Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. *Blood*. 2013; 122:1873–1880. [PubMed: 23798713]
- Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. *Thrombosis and Haemostasis*. 2012; 107:1044–1052. [PubMed: 22535498]
- Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. *American Journal of Hematology*. 2012; 87:340–346. [PubMed: 22307997]
- Gray LD, Hussey MA, Larson BM, Machlus KR, Campbell RA, Koch G, Ezban M, Hedner U, Wolberg AS. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. *Thrombosis Research*. 2011; 128:570–576. [PubMed: 21561645]

- Hamer JD, Malone PC, Silver IA. The PO<sub>2</sub> in venous valve pockets: its possible bearing on thrombogenesis. *British Journal of Surgery*. 1981; 68:166–170. [PubMed: 7470818]
- Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. *New England Journal of Medicine*. 1979; 300:1001–1005. [PubMed: 431593]
- Helley D, Girot R, Guillin MC, Bezeaud A. Sickle cell disease: relation between procoagulant activity of red blood cells from different phenotypes and in vivo blood coagulation activation. *British Journal of Haematology*. 1997; 99:268–272. [PubMed: 9375737]
- Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. *Thrombosis and Haemostasis*. 2006; 96:553–561. [PubMed: 17080210]
- Hillery CA, Panepinto JA. Pathophysiology of stroke in sickle cell disease. *Microcirculation*. 2004; 11:195–208. [PubMed: 15280092]
- Hooper WC, Miller CH, Key NS. Complications associated with carrier status among people with blood disorders: a commentary. *American Journal of Preventive Medicine*. 2010; 38:S456–S458. [PubMed: 20331943]
- Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. *Biochimica et Biophysica Acta*. 1985; 812:55–65. [PubMed: 23008845]
- Hoppe CC. Inflammatory mediators of endothelial injury in sickle cell disease. *Hematology/Oncology Clinics of North America*. 2014; 28:265–286. [PubMed: 24589266]
- Johnson GJ, Leis LA, Bach RR. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty. *Thrombosis and Haemostasis*. 2009; 102:728–734. [PubMed: 19806259]
- Key NS, Derebail VK. Sickle-cell trait: novel clinical significance. *Hematology Am Soc Hematol Educ Program*. 2010; 2010:418–422. [PubMed: 21239829]
- Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. *Seminars in Thrombosis and Hemostasis*. 2010; 36:865–875. [PubMed: 21049387]
- Key NS, Slungaard A, Dandele L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. *Blood*. 1998; 91:4216–4223. [PubMed: 9596669]
- Key NS, Connes P, Derebail VK. Negative health implications of sickle cell trait in developed countries: from the football field to the laboratory. *British Journal of Haematology*. 2015; 170:5–14. [PubMed: 25754217]
- Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. *Journal of Thrombosis and Haemostasis*. 2013; 11:24–35. [PubMed: 23809108]
- Levi M, van der Poll T. Inflammation and coagulation. *Critical Care Medicine*. 2010; 38:S26–S34. [PubMed: 20083910]
- Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. *Current Opinion in Hematology*. 2013; 20:472–477. [PubMed: 23817169]
- Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. *Journal of Thrombosis and Haemostasis*. 2004; 2:1954–1959. [PubMed: 15550027]
- Lutsey PL, Cushman M, Steffen LM, Green D, Barr RG, Herrington D, Ouyang P, Folsom AR. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. *Journal of Thrombosis and Haemostasis*. 2006; 4:2629–2635. [PubMed: 17002663]
- Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. *Thrombosis and Haemostasis*. 2009; 102:936–944. [PubMed: 19888532]
- Naik RP, Streiff MB, Haywood C Jr, Segal JB, Lanzkron S. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. *Journal of Thrombosis and Haemostasis*. 2014; 12:2010–2016. [PubMed: 25280124]
- Noubouossie DC, Le PQ, Rozen L, Ziereisen F, Willems D, Demulder A, Ferster A. Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial


- Doppler velocity, and hydroxyurea treatment. *European Journal of Haematology*. 2013; 91:46–54. [PubMed: 23530655]
- Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV. Pulmonary embolism in sickle cell disease: a case–control study. *Journal of Thrombosis and Haemostasis*. 2012; 10:760–766. [PubMed: 22417249]
- Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. *Circulation Research*. 2011; 108:1284–1297. [PubMed: 21566224]
- Pakbaz Z, Wun T. Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. *Hematology/oncology Clinics of North America*. 2014; 28:355–374. [PubMed: 24589271]
- Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. *Lancet*. 2013; 381:142–151. [PubMed: 23103089]
- Roberts LN, Patel RK, Chitongo P, Bonner L, Arya R. African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. *Blood Coagulation & Fibrinolysis*. 2013; 24:40–49. [PubMed: 23080367]
- Salvagno GL, Lippi G, Montagnana M, Poli G, Giavarina D, Manzato F, Guidi GC. Performance of the automated and rapid HemosIL D-Dimer HS on the ACL TOP analyzer. *Blood Coagulation & Fibrinolysis*. 2008; 19:817–821. [PubMed: 19002050]
- Setty BN, Key NS, Rao AK, Gayen-Betal S, Krishnan S, Dampier CD, Stuart MJ. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. *British Journal of Haematology*. 2012; 157:370–380. [PubMed: 22360627]
- Sevitt S. Organization of valve pocket thrombi and the anomalies of double thrombi and valve cusp involvement. *British Journal of Surgery*. 1974; 61:641–649. [PubMed: 4853490]
- Singhal A, Doherty JF, Raynes JG, McAdam KP, Thomas PW, Serjeant BE, Serjeant GR. Is there an acute-phase response in steady-state sickle cell disease? *Lancet*. 1993; 341:651–653. [PubMed: 7680738]
- Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. *British Journal of Haematology*. 2013; 162:3–14. [PubMed: 23593937]
- Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. *American Journal of Medicine*. 2006; 119(10):897.e7–11. [PubMed: 17000225]
- Tripette J, Connes P, Hedreville M, Etienne-Julan M, Marlin L, Hue O, Hardy-Dessources MD. Patterns of exercise-related inflammatory response in sickle cell trait carriers. *British Journal of Sports Medicine*. 2010; 44:232–237. [PubMed: 18499764]
- Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A, Mannucci PM. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. *Haematologica*. 2009; 94:1520–1527. [PubMed: 19648162]
- Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. *American Journal of Medicine*. 2009; 122:507–512. [PubMed: 19393983]
- Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Schlegel R, Williamson P. Coagulation changes in individuals with sickle cell trait. *American Journal of Hematology*. 2002; 69:89–94. [PubMed: 11835343]



**Fig 1.** Calibrated Automated Thrombography<sup>®</sup> (CAT). CAT assays on platelet poor plasma was performed using 1 pmol/l tissue factor and 4  $\mu$ mol/l phospholipid, supplied by the manufacturer. (A) Time to peak thrombin generation. (B) Endogenous thrombin potential (area under the curve). Data comparing these parameters are shown for control (AA), sickle cell trait (AS) and sickle cell disease (SS) subjects.



**Fig 2.** Fibrin formation. Fibrin formation in platelet poor plasma was measured using a turbidimetric assay as described in Methods. Data shown are for onset time for clot formation for control (AA), sickle cell trait (AS) and sickle cell disease (SS) subjects.



**Fig 3.** Measurement of circulating tissue factor activity. (A) Whole blood tissue factor (WBTF) activity was measured as described in Methods, and the concentration expressed as pmol/l. This assay is sensitive to all membrane-bound tissue factor in blood. (B) Microparticle tissue factor (MPTF) activity was measured on platelet-free plasma, as described in Methods, and the concentration expressed as fmol/l. Both figures show the data for control (AA), sickle cell trait (AS) and sickle cell disease (SS) subjects.

Table 1

Haematological data in study subjects.

Assay	AA (n = 22)	AS (n = 17)	SS (n = 16)	P-value*	P-value <sup>†</sup>
WBC ( $\times 10^9/l$ )	6.1 (5.0–7.4)	6.8 (5.8–7.1)	8.8 (6.7–12.4)	0.5422	0.0105
AMC ( $\times 10^9/l$ )	0.3 (0.3–0.4)	0.4 (0.3–0.5)	0.6 (0.4–0.8)	0.0600	0.0023
ANC ( $\times 10^9/l$ )	3.3 (2.2–4.0)	4.1 (3.2–4.4)	4.1 (3.2–6.0)	0.1563	0.0397
Platelet count ( $\times 10^9/l$ )	285 (255–327)	325 (290–364)	399 (308–512)	0.0474	0.0052
Hb (g/l)	125 (121, 131)	124 (120–137)	86 (82–100)	0.7984	<0.0001
LDH (iu/l)	463 (436–525)	518 (454–558)	1022 (905–1144)	0.2549	<0.0001
Haptoglobin (mg/l)					
<220	0 (0%)	2 (12%)	14 (93%)	0.0553	<0.0001
220–1390	10 (45%)	11 (65%)	1 (7%)		
>1390	12 (55%)	4 (24%)	0 (0%)		

Data are presented as median (interquartile range) or n (%).

AA, HbAA individuals (controls); AS, HbAS individuals (sickle cell trait); SS, HbSS individuals (sickle cell disease); WBC, white blood cell count; Hb, haemoglobin concentration; LDH, lactate dehydrogenase; AMC, absolute neutrophil count; ANC, absolute monocyte count.

\* Comparison of AA to AS.

† Comparison of AA to SS.



Table II

Coagulation data in study subjects.

Analyte	AA (n = 22)	AS (n = 17)	SS (n = 16)	P-value*	P-value <sup>†</sup>
D-Dimer (µg/ml)					
<150	14 (64%)	3 (18%)	0 (0%)	0.0171	<0.0001
150-229	3 (14%)	4 (24%)	0 (0%)		
>229	5 (23%)	10 (29%)	16 (100%)		
TAT (nmol/l)	0.02 (0.02–0.02)	0.03 (0.02–0.97)	3.04 (0.03–8.78)	0.0385	<0.0001
Whole blood tissue factor activity (pmol/l)	0.08 (0.04–0.14)	0.09 (0.04–0.11)	0.23 (0.09–0.33)	0.7337	0.0048
Microparticle tissue factor activity (fmol/l)	2.2 (0–3.5)	3.8 (2.8–6.9)	5.5 (4.5–9.3)	0.0513	0.0042

Data are presented as median (IQR) or n (%).

AA, HbAA individuals (controls); AS, HbAS individuals (sickle cell trait); SS, HbSS individuals (sickle cell disease); TAT, thrombin-antithrombin complex.

\* Comparison of AA to AS.

† Comparison of AA to SS.

**Table III**

Thrombin generation and plasma clot formation parameters.

Parameter	AA (n = 21)	AS (n = 16)	SS (n = 17)	P-value*	P-value†
Thrombin generation					
Lag time (min)	5.3 (4.8–6.3)	5.2 (4.7–5.7)	5.1 (4.2–5.5)	0.4433	0.1052
Time to peak (min)	9.9 (9.2–10.7)	10.4 (9.2–11.4)	8.1 (7.7–9.1)	0.6693	0.0001
Thrombin peak (nmol/l)	163.6 (128.8–206.6)	168.3 (130.6–233.1)	203.2 (173.1–232.8)	0.6826	0.0887
ETP (nmol/l × min)	1496.0 (1431.5–1770.8)	1623.4 (1395.1–1851.5)	1217.5 (1170.0–1329.5)	0.4573	<0.0001
Clotting					
Onset (min)	15.0 (12.0–16.5)	12.3 (10.4–15.4)	11.6 (8.9–14.8)	0.2802	0.0418
Rate (mOD/min)	78.6 (52.4–99.3)	60.8 (40.7–83.7)	83.8 (55.4–120.9)	0.2060	0.2943
Change in turbidity	0.70 (0.57–0.78)	0.68 (0.61–0.76)	0.67 (0.56–0.77)	0.9638	0.7277

Data are presented as median (IQR).

AA, HbAA individuals (controls); AS, HbAS individuals (sickle cell trait); SS, HbSS individuals (sickle cell disease); ETP, endogenous thrombin potential; mOD, mean optical density.

\* Comparison of AA to AS.

† Comparison of AA to SS.